Drug Profile


Alternative Names: CBLB 502

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Cleveland BioLabs
  • Class Anti-ischaemics; Antidotes; Chemoprotectants; Peptides
  • Mechanism of Action Apoptosis inhibitors; Apoptosis stimulants; NF-kappa B modulators; Toll-like receptor 5 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Acute radiation syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer
  • Phase I Acute radiation syndrome
  • Preclinical Radioprotection
  • No development reported Reperfusion injury

Most Recent Events

  • 27 Feb 2017 Baylor College of Medicine in collaboration with National Institutes of Health plans a phase I trial for Substance related disorders in USA (NCT03063736)
  • 14 Nov 2016 Cleveland BioLabs completes enrollment in the phase II trial for Cancer (First-line therapy, Neoadjuvant therapy) in Russia (NCT02715882; 9207054)
  • 19 Aug 2016 Clinical development is ongoing in USA and Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top